Search Result

Results for "

AR protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (4) Adrenergic Receptor (6) AMPK (1) Androgen Receptor (46) Apoptosis (13) Autophagy (1) AUTOTACs (1) Biochemical Assay Reagents (1) c-Myc (1) Caspase (3) CDK (2) Complement System (3) DNA Methyltransferase (1) Dopamine Receptor (1) Drug Intermediate (2) Epigenetic Reader Domain (5) ERK (1) FAP (1) G protein-coupled Bile Acid Receptor 1 (1) HSP (1) Influenza Virus (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Ligands for E3 Ligase (5) Ligands for Target Protein for PROTAC (12) Mitophagy (1) MNK (1) Molecular Glues (2) Monoamine Transporter (1) Oxytocin Receptor (2) Polo-like Kinase (PLK) (1) PROTAC Linkers (1) PROTACs (15) PSMA (2) Reference Standards (3) ROCK (3) Ser/Thr Protease (1) SNIPERs (2) Vasopressin Receptor (2)
By Research Areas:	Cancer (52) Cardiovascular Disease (6) Endocrinology (11) Infection (2) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (8)
Click Chemistry:	PROTAC Synthesis (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111848A

PROTAC AR Degrader-4 TFA	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-160262

*AR/BET protein* degrader-1**	Androgen Receptor PROTACs Epigenetic Reader Domain	Cancer
AR/BET protein degrader-1 (Compound 149) is an Androgen Receptor and BET (bromodomain and extra-terminal domain) protein degrader that can be used in cancer research .

HY-173373

AR ligand-39	Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
AR ligand-39, an orally active and selective androgen receptor (AR) antagonist, is a PROTAC target protein ligand (*Ligand for Target Protein* for PROTAC**). AR ligand-39 can be used for synthesis PROTAC AR Degrader-10 (HY-173372) .

HY-149434

PROTAC AR-NTD degrader 1	Androgen Receptor Apoptosis	Cancer
PROTAC AR-NTD antagonist 1 (compound 18) is a small molecule protein-targeting chimera (PROTACs) targeting the Androgen Receptor AR-V7. PROTAC AR-NTD antagonist 1 antagonizes the N-terminal domain of AR (AR-NTD), degrades AR-V7 protein, and induces apoptosis in prostate cancer (PC) cells. The efficiencies of PROTAC AR-NTD antagonist 1 in degrading AR-V7 in VCaP cells were 62.2% (1 μM) and 71.1% (5 μM), respectively .

HY-176129

AR ligand 41	Ligands for Target Protein for PROTAC	Cancer
AR ligand 41 is a PROTAC target protein ligand (*Ligands for Target Protein* for PROTACs**). AR ligand 41 can be used for the synthesis of BWA-6047 (HY-176128) .

HY-170303

AR ligand-32	Ligands for Target Protein for PROTAC	Cancer
AR ligand-32 is a target protein ligand, used for the synthesis of PROTAC AR Degrader-7 (HY-160221) .

HY-174391

AR antagonist 15	Androgen Receptor Apoptosis	Cancer
AR antagonist 15 is an orally active androgen receptor (AR) antagonist with the IC₅₀ of 97 nM for AR^T787A. AR antagonist 15 disrupts AR nuclear translocation, hinders AR homodimerization, and suppresses transcription of AR-regulated genes by competitive binding to the ligand binding pocket. AR antagonist 15 can significantly lower the prostate-specific antigen (PSA) level. AR antagonist 15 induces apoptosis by reducing the expression of apoptosis pathway related proteins. AR antagonist 15 can be used for the research of prostate cancer.

HY-169967

AR ligand-31	Ligands for Target Protein for PROTAC	Cancer
AR ligand-31 is a PROTAC target protein ligand that can be used to synthesize PROTAC AR Degrader-5 (HY-160547) .

HY-111848

PROTAC AR Degrader-4	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-173372

PROTAC AR Degrader-10	Androgen Receptor	Cancer
PROTAC AR Degrader-10 is a protein degrader targeting the androgen receptor (AR) with a DC₅₀ value ≤100 nM. PROTAC AR Degrader-10 can be used for prostate cancer study. (Structure Note: Pink: target protein ligand (HY-173373); Blue: E3 ligase ligand (HY-138793); Black: linker) .

HY-170330

AR ligand-33	Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
AR ligand-33 is the ligand for androgen receptor, that can be used for synthesis of PROTAC AR Degrader-8 (HY-170329) as the target protein ligand .

HY-173559

AR antagonist 12	Androgen Receptor	Cancer
AR antagonist 12 (compound 20i) is an orally active androgen receptor antagonist wiith IC₅₀ values of 119.3 μM and 98.2 μM for wt-AR and AR-F877L,respectively. AR antagonist 12 induces a dose-dependent and time-dependent reduction in AR, AR-V7, and PSA protein levels. AR antagonist 1 shows anticancer activuty and can be used for the study of Enzalutamide (HY-70002)-resistant Prostate cancer .

HY-173409

AR antagonist 11	Androgen Receptor Ser/Thr Protease	Inflammation/Immunology
AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC₅₀ of 0.019 μM. AR antagonist 11 is also effective against AR ^F877L/T878A mutant (IC₅₀: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC₅₀: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa) .

HY-174157

AR493	Autophagy AMPK	Neurological Disease Metabolic Disease
AR493 is an autophagy activator acting on AMPK (adenosine monophosphate-activated protein kinase). AR493 regulates pathways related to cellular energy sensing and increases autophagy levels. AR493 is promising for research of aging-associated diseases (such as diabetes, neurodegenerative diseases) and autophagy regulation .

HY-176067

LO-4-25	Androgen Receptor	Cancer
LO-4-25 is a covalent degrader targeting the androgen receptor (AR) and its truncated variant *AR-V7. LO-4-25 covalently binds to the E3 ubiquitin ligase CUL4 DCAF16, promoting the ubiquitination of AR and AR-V7, which subsequently are recognized and degraded by the proteasome, reducing the protein* levels of AR and AR-V7 in cells. LO-4-25 is promising for research of androgen-independent prostate cancers .

HY-172624

AR antagonist 14	Ligands for Target Protein for PROTAC	Cancer
AR antagonist 14 is is a PROTAC target protein ligand (*Ligands for Target Protein* for PROTAC**). AR antagonist 14 can be combined with VH 101-amide-piperidine-Pip-alkyne (HY-172625) to synthesize PROTAC degraders (ARD-69 (HY-114402)) .

HY-150025

(4aS,8aR)-NPD-001	DNA Methyltransferase Apoptosis	Cancer
(4aS,8aR)-NPD-001 is a potent and allosteric inhibitor of DNMT3A. (4aS,8aR)-NPD-001 inhibits DNMT3A activity by disrupting protein-protein interactions. (4aS,8aR)-NPD-001 induces apoptosis of acute myeloid leukemia (AML) cell lines. (4aS,8aR)-NPD-001 induces differentiation of distinct AML cell lines including cells with mutated DNMT3A R882 .

HY-W653723

N-Nitrosodicyclohexylamine NDCHA	Androgen Receptor	Endocrinology
N-Nitrosodicyclohexylamine (NDCHA) is a N-nitrosocompound with anti-androgenic activities. N-Nitrosodicyclohexylamine shows the competitive binding to androgen receptor (AR) against 5α-dihydrotestosterone and decreased the level of AR protein .

HY-130845

AR antagonist 1	Ligands for E3 Ligase Ligands for Target Protein for PROTAC	Cancer
AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).

HY-130992

Androgen receptor antagonist 1	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC₅₀ of 59 nM . Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively .

HY-132292

ARD-2128	PROTACs Androgen Receptor	Cancer
ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer .

HY-164552

ZNU-IMB-Z15	Apoptosis Androgen Receptor	Cancer
ZNU-IMB-Z15 (Compound Z15) is an antagonist of the androgen receptor (AR) and also a selective degrader of AR and ARV7. ZNU-IMB-Z15 can directly bind to the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. ZNU-IMB-Z15 effectively inhibits the transcriptional activity of AR, AR mutants, and AR splice variants (ARVs), downregulating the mRNA and protein levels of AR downstream target genes, thereby overcoming the resistance to second-generation antiandrogen drugs induced by AR LBD mutations, AR amplification, and ARVs in castration-resistant prostate cancer (CRPC). ZNU-IMB-Z15 can inhibit the proliferation of AR-positive CRPC cell lines and induce their apoptosis, demonstrating anticancer activity both in vivo and in vitro .

HY-130845A

AR antagonist 1 hydrochloride	Ligands for E3 Ligase Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
AR antagonist 1 (compound 29) hydrochloride is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020) .

HY-400766

BWA-522 intermediate-2	Drug Intermediate	Cancer
BWA-522 intermediate-2 is a BWA-522 intermediate. BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7 .

HY-401056

BWA-522 intermediate-3	Drug Intermediate	Cancer
BWA-522 intermediate-3 is a BWA-522 intermediate. BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7 .

HY-121588

IMTPPE	Adrenergic Receptor	Cancer
IMTPPE is an inhibitor of the androgen receptor (AR) in C4-2 prostate cancer cells, inhibiting its transcriptional activity and protein levels. IMTPPE inhibited the proliferation of AR-positive prostate cancer cells but had no effect on AR-negative prostate cancer cells. IMTPPE also inhibited the growth of enzalutamide-resistant 22Rv1 xenograft tumors .

HY-148777

A031	PROTACs Androgen Receptor	Cancer
A031 is a highly effective PROTAC androgen receptor (AR) degrader with an IC₅₀ value less than 0.25 μM for AR protein degradation. A031 has an inhibitory effect on tumor growth in zebrafish with human prostate cancer (VCaP) .

HY-110202

MRS5698	Adenosine Receptor	Neurological Disease Inflammation/Immunology
MRS5698 is a selective G_i protein-coupled A₃ adenosine receptor (A₃AR) agonist, with K_is of approximately 3 nM for human and mouse A₃AR, respectively. MRS5698 can be used for the research of pain and psoriasis .

HY-160547

PROTAC AR Degrader-5	PROTACs Androgen Receptor	Metabolic Disease
PROTAC AR Degrader-5 (compound A46) is a potent AR PROTACs degrader with an IC₅₀ value of 49 nM. PROTAC AR Degrader-5 inhibits sebaceous plaque and induces hair regeneration (Pink: ligand for target protein (HY-169967); black: linker (HY-169966); Blue: E3 ligase ligand (HY-125845)) .

HY-161409

SC912	Androgen Receptor Apoptosis	Cancer
SC912 is an *AR-V7* inhibitor (IC₅₀ = 0.36 μM). SC912 possesses safety, potency and selectivity. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis .

HY-168697

AR ligand-37	Ligands for Target Protein for PROTAC	Cancer
AR ligand-37 is a PROTAC target protein ligand that can be used to synthesize BMS-986365 (HY-158101) .

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-168299

AR ligand-30	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
AR ligand-30 is a target protein ligand for PROTAC Bavdegalutamide (HY-138641), which can be used in prostate cancer research .

HY-W653723R

N-Nitrosodicyclohexylamine (Standard) NDCHA (StandARd)	Reference Standards Androgen Receptor	Endocrinology
N-Nitrosodicyclohexylamine (Standard) is the analytical standard of N-Nitrosodicyclohexylamine. This product is intended for research and analytical applications. N-Nitrosodicyclohexylamine (NDCHA) is a N-nitrosocompound with anti-androgenic activities. N-Nitrosodicyclohexylamine shows the competitive binding to androgen receptor (AR) against 5α-dihydrotestosterone and decreased the level of AR protein .

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM .

HY-170448

PROTAC AR Degrader-9	PROTACs Androgen Receptor	Endocrinology
PROTAC AR Degrader-9 (Compound c6) is a PROTAC degrader for androgen receptor, that degrades AR in human hair follicle papilla cells (HDPCs) with a DC₅₀ of 262.38 nM. PROTAC AR Degrader-9 promotes the expressions of paracrine factors, such as TGF-β1 and β-catenin, exhibits hair regenerating efficacy in mouse models . (Pink: ligand for target protein AR ligand-38 (HY-170450); Black: linker; Blue: ligand for E3 ligase Cereblon (HY-170449))

HY-19319

MI-136	Epigenetic Reader Domain Androgen Receptor Apoptosis	Cancer
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC₅₀ of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .

HY-149862

ARD-2051	PROTACs Androgen Receptor	Cancer
ARD-2051 is a potent and orally active androgen receptor *(AR)* proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .

HY-B1421

Ractopamine hydrochloride LY031537	Adrenergic Receptor	Metabolic Disease
Ractopamine (LY031537) hydrochloride is a potent β-adrenergic receptor (βAR) agonist with K_d value of ~25 nM for pig β₁AR and β₂AR. Ractopamine hydrochloride is linked to protein metabolism. Ractopamine hydrochloride can be used for researching to increase lean tissue growth and improve production efficiency in pigs .

HY-120006A

(rel)-AR234960 1 Publications Verification	ERK	Cardiovascular Disease
(rel)-AR234960 is a selective and competitive agonist of the *G protein-coupled receptor MAS. (rel)-AR234960 binds to the MAS receptor to activate the downstream ERK1/2* signaling pathway, inducing the expression of connective tissue growth factor (CTGF) and its downstream collagen subtype genes (such as COL1A1, COL3A1). (rel)-AR234960 promotes collagen synthesis in cardiac fibroblasts through the MAS-ERK1/2-CTGF pathway and aggravates extracellular matrix remodeling. (rel)-AR234960's in vitro effect can be blocked by the MAS inverse agonist AR244555 and MEK1 inhibitor. (rel)-AR234960 regulates the expression of cardiac fibrosis-related genes and can be used in the study of heart failure .

HY-168296

AR ligand-29	Ligands for Target Protein for PROTAC	Cancer
AR ligand-29 is the target protein ligand of PROTAC VinclozolinM2-2204 (HY-161741), which can be used for cancer research .

HY-170329

PROTAC AR Degrader-8	PROTACs Androgen Receptor Apoptosis	Cancer
PROTAC AR Degrader-8 (Compound NP18) is the PROTAC degrader for androgen receptor (AR), that degrades *AR-FL* with DC₅₀ of 0.018 μM and 0.14 μM in 22Rv1 cell and LNCaP cell, degrades *AR-V7* with DC₅₀ of 0.026 μM in 22Rv1 cell. PROTAC AR Degrader-8 inhibits the proliferation of cancer cell 22Rv1 and LNCaP with IC₅₀ of 0.038 μM and 1.11 μM. PROTAC AR Degrader-8 arrests cell cycle at G2/M phase, induces apoptosis in 22Rv1 cell. PROTAC AR Degrader-8 exhibits anticancer efficacy in mouse and zebrafish model . (Pink: ligand for target protein AR ligand-33 (HY-170330); Black: linker (HY-W007731); Blue: ligand for E3 ligase Cereblon (HY-14658))

HY-158882

FLAC6	Biochemical Assay Reagents Adenosine Receptor	Others
FLAC6 is a potent fluorinated detergent that can be used to solubilize membrane proteins (the native adenosine receptor *A_2AR, a G protein-coupled receptor, and two native transporters AcrB* and BmrA). FLAC6 can maintain the structural and functional integrity of different membrane proteins .

HY-114402

ARD-69	PROTACs Androgen Receptor	Cancer
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor, which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells. ARD-69 inhibits AR-regulated gene expression, binds to the AR ligand binding domain at one end and binds to VHL at the other end, prompting AR to be recruited to the E3 ubiquitin ligase complex, triggering proteasome degradation, thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA, TMPRSS2). ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC) . ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624), a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and a VHL-type E3 ubiquitinase ligand (blue part) VH 101, acid (HY-47070); among them, the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyne (HY-172625).

HY-169385

ATC-324	AUTOTACs Androgen Receptor	Cancer
ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).

HY-W877989

BWA-522 intermediate-1	Ligands for E3 Ligase	Cancer
BWA-522 intermediate-1 is an intermediate in the synthesis of PROTAC BWA-522 (HY-149433) and serves as a ligand molecule for cereblon E3 ubiquitin ligase. BWA-522 is an orally active small molecule protein-targeting chimera (PROTAC) that has significant degradation effects on AR-FL and AR-V7 .

HY-148361

Fluorogen binding modulator-1	FAP	Others
Fluorogen binding modulator-1 (PubChem SID 125240934) is a *fluorogen activating protein* (FAP)-fluorogen binding modulator with -log EC₅₀**s of 6.61 and 6.37 for AM2.2-β2AR and AM2.2-GPR32, respectively .

HY-124292

Honokiol DCA 1 Publications Verification Honokiol dichloroacetate	Androgen Receptor	Cancer
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .

HY-133020

ARD-266	PROTACs Androgen Receptor	Cancer
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157491

K2-B4-5e	PROTACs Androgen Receptor Epigenetic Reader Domain	Cancer
K2-B4-5e is a E3 ligase KLHDC2-based BRD4 and androgen receptor (AR) degradation PROTAC. K2-B4-5e is capable of inducing rapid and robust degradation of BET-family and AR proteins in cells .

Cat. No.	Product Name

HY-L129

Target Protein Ligand Library

62 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 62 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.	Product Name	Target	Research Area

HY-P5213

Vasopressin Dimer (parallel) (TFA)	Vasopressin Receptor Oxytocin Receptor	Endocrinology
Vasopressin Dimer (parallel) TFA is a parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (parallel) TFA can activate four G protein-coupled receptors, *V1aR, V1bR, V2R, and OTR* .

HY-P1345A

TLQP-21 TFA 2 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P5214

Vasopressin Dimer (anti-parallel) (TFA)	Vasopressin Receptor Oxytocin Receptor	Endocrinology
Vasopressin Dimer (anti-parallel) TFA is an anti-parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (anti-parallel) TFA can activate four G protein-coupled receptors, *V1aR, V1bR, V2R, and OTR* .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7045

Isosilybin B 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-N7045R

Isosilybin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

Species:	Human (11) Mouse (5) Cynomolgus (1)
Tag:	His (10) Tag Free (6) Avi (4) GST (1) Fc (2)
Source:	HEK293 (10) P. pastoris (2) Sf9 insect cells (1) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P71730

	*EDNRA Protein, Human (P.pastoris, His)* Ednra; ET A; ET-A; ETA; ETA R; ETA-R; ETAR; ETRA; G protein coupled receptor; hET AR; hET-AR; MFDA	Human	P. pastoris
	EDNRA Protein, a receptor for endothelin-1, activates a phosphatidylinositol-calcium second messenger system through association with G proteins. Its binding affinities follow the order: ET1 > ET2 >> ET3. Additionally, EDNRA interacts with HDAC7 and KAT5. EDNRA Protein, Human (P.pastoris, His) is the recombinant human-derived EDNRA protein, expressed by P. pastoris , with N-His labeled tag.

HY-P7002

	*Amphiregulin Protein, Human (HEK293)* 2 Publications Verification rHuAmphiregulin; AR; AREG; Colorectum cell-derived growth factor; CRDGF	Human	HEK293
	Amphiregulin Protein, Human (HEK293) is an EGF receptor (EGFR) ligand, and essential for epithelial development in various organs.

HY-P70578

	*Amphiregulin Protein, Human* Amphiregulin; AR; Colorectum Cell-Derived Growth Factor; CRDGF; AREG; SDGF; AREGB	Human	E. coli
	Amphiregulin Protein, an EGFR ligand, serves as an autocrine growth factor and mitogen for various cells, including astrocytes, Schwann cells, and fibroblasts. It promotes cellular proliferation and interacts with CNIH in its immature precursor stage. Amphiregulin's EGFR activation underscores its role in essential cellular processes, emphasizing its significance as a regulator of cell growth and function in diverse cell types. Amphiregulin Protein, Human is the recombinant human-derived Amphiregulin protein, expressed by E. coli , with tag free.

HY-P77868

	*Amphiregulin Protein, Mouse (HEK293, Fc)* 2 Publications Verification Amphiregulin; AR; SDGF; AREG; AREGB; CRDGF; MGC13647	Mouse	HEK293
	Amphiregulin Protein, an EGFR ligand, acts as an autocrine growth factor and mitogen for diverse cells, including astrocytes, Schwann cells, and fibroblasts. Engaging with CNIH in its immature stage, Amphiregulin's EGFR activation emphasizes its vital role in regulating cell growth and orchestrating various cellular functions across different cell types. Amphiregulin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Amphiregulin protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P702502

	*Amphiregulin Protein, Mouse* Amphiregulin; AR; AREG; AREGB; Colorectum cell-derived growth factor; CRDGF; MGC13647; schwannoma-derived growth factor; SDGF	Mouse	E. coli
	Amphiregulin Protein is marked by a deficiency in conserved residue(s) essential for the propagation of feature annotation. Amphiregulin Protein, Mouse is the recombinant mouse-derived Amphiregulin protein, expressed by E. coli , with tag free.

HY-P704116

	*EDNRA Protein, Human (His)* Ednra; ET A; ET-A; ETA; ETA R; ETA-R; ETAR; ETRA; G protein coupled receptor; hET AR; hET-AR; MFDA	Human	E. coli
	EDNRA Protein, a receptor for endothelin-1, activates a phosphatidylinositol-calcium second messenger system through association with G proteins. Its binding affinities follow the order: ET1 > ET2 >> ET3. Additionally, EDNRA interacts with HDAC7 and KAT5. EDNRA Protein, Human (His) is the recombinant human-derived EDNRA protein, expressed by E. coli, with C-10*His labeled tag.

HY-P704570

	*EDNRA Protein-VLP, Human (HEK293)* Ednra; ET A; ET-A; ETA; ETA R; ETA-R; ETAR; ETRA; G protein coupled receptor; hET AR; hET-AR; MFDA	Human	HEK293
	EDNRA Protein, a receptor for endothelin-1, activates a phosphatidylinositol-calcium second messenger system through association with G proteins. Its binding affinities follow the order: ET1 > ET2 >> ET3. Additionally, EDNRA interacts with HDAC7 and KAT5. EDNRA Protein-VLP, Human (HEK293) is the recombinant human-derived EDNRA protein, expressed by HEK293, with tag free.

HY-P705411

	*SRD5A1 Protein, Human (His)* SR type 1; Steroid 5-alpha-reductase 1; S5AR 1	Human	E. coli

HY-P701871

	*GRE3 Protein, Saccharomyces cerevisiae* GRE3; NADPH-dependent aldose reductase GRE3; AR; Genes de respuesta a estres protein 3; NADPH-dependent aldo-keto reductase GRE3; Xylose reductase	Others	E. coli
	The GRE3 protein is an aldose reductase that reduces the cytotoxic compound methylglyoxal (MG) to acetol and (R)-lactaldehyde, especially under stress conditions. MG is synthesized from dihydroxyacetone phosphate and is involved in cell cycle regulation and stress adaptation. GRE3 Protein, Saccharomyces cerevisiae is the recombinant GRE3 protein, expressed by E. coli , with tag free.

HY-P701872

	*GRE3 Protein, Saccharomyces cerevisiae (His)* GRE3; NADPH-dependent aldose reductase GRE3; AR; Genes de respuesta a estres protein 3; NADPH-dependent aldo-keto reductase GRE3; Xylose reductase	Others	E. coli
	The GRE3 protein is an aldose reductase that reduces the cytotoxic compound methylglyoxal (MG) to acetol and (R)-lactaldehyde, especially under stress conditions. MG is synthesized from dihydroxyacetone phosphate and is involved in cell cycle regulation and stress adaptation. GRE3 Protein, Saccharomyces cerevisiae (His) is the recombinant GRE3 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P71786

	*Osteopontin/OPN Protein, Mouse (P.pastoris, His)* 1 Publications Verification Spp1; Eta-1; Op; Spp-1; Osteopontin; 2AR; Minopontin; Secreted phosphoprotein 1; SPP-1	Mouse	P. pastoris
	Osteopontin/OPN Protein, a crucial non-collagenous bone protein, binds strongly to hydroxyapatite, integral to the mineralized matrix.It likely plays a vital role in mediating cell-extracellular matrix interactions.Moreover, as a cytokine, OPN efficiently induces interferon-gamma and interleukin-12 production while inhibiting interleukin-10, pivotal in promoting type I immunity.Osteopontin/OPN Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Osteopontin/OPN protein, expressed by P.pastoris , with N-6*His labeled tag.

HY-P702895

	*PPP2CA-PPP2R1A Protein, Human (sf9, GST)* protein phosphatase 2A catalytic subunit α; TPD3; RP-C; PP2Ac,PPP2CA; protein phosphatase 2A regulatory subunit; PP2AR	Human	Sf9 insect cells
	PPP2CA-PPP2R1A Protein, Human (sf9, GST) is the recombinant human-derived PPP2CA-PPP2R1A, expressed by Sf9 insect cells , with N-GST labeled tag. ,

HY-P78308

	*IFNAR1 Protein, Mouse (HEK293, Fc)* AVP; IFN-alpha/beta R1; IFN-alpha-REC; IFNAR; IFNAR1; IFN-AR1; IFNBR; IFNbR1; IFN-R-1; CRF2-1; IFRC ; IFN-alpha/β R1	Mouse	HEK293
	IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Mouse (HEK293, Fc) is a recombinant mouse IFNAR1 (E27-T429) with C-terminal hFc tag, which is produced in HEK293 cells.

HY-P78309

	*IFNAR1 Protein, Mouse (HEK293, His-Avi)* AVP; IFN-alpha/beta R1; IFN-alpha-REC; IFNAR; IFNAR1; IFN-AR1; IFNBR; IFNbR1; IFN-R-1; CRF2-1; IFRC ; IFN-alpha/β R1	Mouse	HEK293
	IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Mouse (HEK293, Fc) is a recombinant mouse IFNAR1 (E27-T429) with C-terminal His and Avi tags, which is produced in HEK293 cells.

HY-P78457

	*IFNAR1 Protein, Human (HEK293, His-Avi)* AVP; IFN-alpha/beta R1; IFN-alpha-REC; IFNAR; IFNAR1; IFN-AR1; IFNBR; IFNbR1; IFN-R-1; CRF2-1; IFRC ; IFN-alpha/β R1	Human	HEK293
	IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Human (HEK293, His-Avi) is a recombinant human IFNAR1 (K28-K436) with C-terminal His and Avi tag, which is produced in HEK293 cells.

HY-P700899

	*ADORA2A Protein-VLP, Human (HEK293)* ADORA2A; adenosine A2a receptor; ADORA2; adenosine receptor A2a; RDC8; adenosine A2 receptor; adenosine receptor subtype A2a; hA2AR;	Human	HEK293
	ADORA2A Protein-VLP, a receptor for adenosine, activates adenylyl cyclase through G proteins. Its direct interaction with USP4 and GAS2L2 in the cytoplasmic C-terminal domain suggests regulatory roles. Interactions with DRD4 and NECAB2 imply involvement in diverse cellular signaling pathways. ADORA2A Protein-VLP, Human (HEK293) is the recombinant human-derived ADORA2A protein-VLP, expressed by HEK293 , with tag free.

HY-P78141

	*IFNAR1 Protein, Human (Biotinylated, HEK293, His-Avi)* AVP; IFN-alpha/beta R1; IFN-alpha-REC; IFNAR; IFNAR1; IFN-AR1; IFNBR; IFNbR1; IFN-R-1; CRF2-1; IFRC ; IFN-alpha/β R1	Human	HEK293
	IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Human (Biotinylated, HEK293, His-Avi) is a biotinylated recombinant human IFNAR1 (K28-K436) with C-terminal His and Avi tag, which is produced in HEK293 cells.

HY-P703993

	*IFNAR1 Protein, Cynomolgus (Biotinylated, HEK293, His, Avi)* AVP; IFN-alpha/beta R1; IFN-alpha-REC; IFNAR; IFNAR1; IFN-AR1; IFNBR; IFNbR1; IFN-R-1; CRF2-1; IFRC ; IFN-alpha/β R1	Cynomolgus	HEK293
	IFNAR1 Protein, Cynomolgus (Biotinylated, HEK293, His, Avi) is the recombinant cynomolgus-derived IFNAR1 protein, expressed by HEK293, with C-Avi & C-His tag.

HY-P700398

	*C5AR1 Protein-VLP, Human (HEK293, His)* complement component 5a receptor 1; C5R1, complement component 5 receptor 1 (C5a ligand); C5a anaphylatoxin chemotactic receptor; C5A; C5AR; CD88; C5a-R; C5a ligand; C5a anaphylatoxin receptor; complement component 5 receptor 1; C5R1;	Human	HEK293
	C5AR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-135794S

11-Ketodihydrotestosterone-d3

11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a K_i of 20.4 nM and an EC₅₀ of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84934

	NCOA4 Antibody (YA4630) 70 kDa androgen receptor activator antibody; 70 kDa androgen receptor coactivator antibody; 70 kDa AR activator antibody; 70 kDa AR-activator antibody; Androgen receptor coactivator 70 kD antibody; Androgen receptor coactivator 70 kDa protein antibody; Androgen receptor-associated protein of 70 kDa antibody; ARA 70 antibody; ARA70 antibody; DKFZp762E1112 antibody; ELE 1 antibody; ELE1 antibody; ELE1/ret TK antibody; NCOA 4 antibody; NCoA-4 antibody; NCOA4 antibody; NCOA4_HUMAN antibody; NucleAR receptor coactivator 4 antibody; PapillARy thyroid cARcinoma 3 antibody; PTC 3 antibody; PTC3 antibody; RET activating gene ELE1 antibody; Ret activating protein ELE1 antibody; Ret-activating protein ELE1 antibody; RFG antibody	WB	Human
	NCOA4 Antibody (YA4630) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA4630), targeting NCOA4. NCOA4 Antibody (YA4629) can be used for WB experiment in human background.

HY-P84935

	NCOA4 Antibody (YA4631) 70 kDa androgen receptor activator antibody; 70 kDa androgen receptor coactivator antibody; 70 kDa AR activator antibody; 70 kDa AR-activator antibody; Androgen receptor coactivator 70 kD antibody; Androgen receptor coactivator 70 kDa protein antibody; Androgen receptor-associated protein of 70 kDa antibody; ARA 70 antibody; ARA70 antibody; DKFZp762E1112 antibody; ELE 1 antibody; ELE1 antibody; ELE1/ret TK antibody; NCOA 4 antibody; NCoA-4 antibody; NCOA4 antibody; NCOA4_HUMAN antibody; NucleAR receptor coactivator 4 antibody; PapillARy thyroid cARcinoma 3 antibody; PTC 3 antibody; PTC3 antibody; RET activating gene ELE1 antibody; Ret activating protein ELE1 antibody; Ret-activating protein ELE1 antibody; RFG antibody	IHC-P, IF-Tissue	Human, Mouse, Rat
	NCOA4 Antibody (YA4631) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA4631), targeting NCOA4. NCOA4 Antibody (YA4631) can be used for IHC-P, IF-Tissue experiment in Human, Mouse, Rat background.